What’s Next in Preclinical Cancer Immunotherapy Research?
As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies like checkpoint inhibitors still showing variable outcomes in patients, these models present a promising leap toward more personalized and effective treatments.
How can cutting-edge in vitro platforms refine cancer immunotherapy development and bring us closer to clinical precision?
This episode of Crown BioScience, hosted by Liam Sanio, Senior Project Manager at Scientist.com, features a thought-provoking discussion with Dr. Gera Goverse (Director of Immuno-Oncology), Dr. Leo Price (SVP, In Vitro & Head of Crown BioScience Netherlands), and Dr. Ludovic Bourre (VP of Research & Innovation). Together, they explore the promise of organoid technology, patient-derived assays, and AI-powered imaging in the future of immuno-oncology.
Key highlights from the episode:
-
Organoid Models with Immune Integration: Organoids are now used in co-cultures with T cells, myeloid cells, and stromal components to better replicate immune responses and the tumor microenvironment in vitro.
-
Ex Vivo Patient Tissue as a Translational Tool: Tissue obtained directly from surgery is used in assays within 24 hours to preserve native immune context, enabling checkpoint inhibitor sensitivity testing.
-
AI and Multi-Omics for Deeper Insights: AI-powered high-content imaging combined with genomic and proteomic profiling enables biomarker discovery and better stratification of therapeutic responses.
Dr. Gera Goverse leads Crown BioScience’s immuno-oncology strategy, leveraging her extensive experience in TME modulation and translational assay development.
Dr. Leo Price oversees in vitro initiatives and previously spearheaded innovation at OcellO BV, focusing on 3D assay technologies and drug discovery.
Dr. Ludovic Bourre brings a strong background in immunology and systems biology, driving integrated research strategies for IO therapeutics at Crown BioScience.
